RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway April 18, 2024 - AACR2024 reports that biotech has emerged from a "nuclear winter" in biotech which lasted 2 years and affected the funding environment for most biotech companies.
In contrast ONCY was able to raise the funding necessary to continue advancing its "vaccine" platform asset pelareorep towards pivotal registration studies that putatively will result in the FDA's marketing approval and acquisition of the company. This achievement came at a time when other biotech companies were 'cash-starved', and goes against anything that posters like inthno aka De_man have been posting.
In the process, oncolytic virus / vaccine therapy has re-emerged as a cancer treatment that has gained significant attention amongst clinical oncologists, as AACR24 reported. Furthermore, orphan/rare diseases with unment treatment needs, like metastatic pancreatic and breast cancer, have become the focus of interest with those attendfing the conference.